IN2012DN00446A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00446A
IN2012DN00446A IN446DEN2012A IN2012DN00446A IN 2012DN00446 A IN2012DN00446 A IN 2012DN00446A IN 446DEN2012 A IN446DEN2012 A IN 446DEN2012A IN 2012DN00446 A IN2012DN00446 A IN 2012DN00446A
Authority
IN
India
Prior art keywords
immunogens
compositions
tau
medicine
treatment
Prior art date
Application number
Other languages
English (en)
Inventor
Iii George Joseph Smith
Kenneth Nelson Wills
Jeff Xianchao Zhu
Original Assignee
Pfizer Vaccines Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Vaccines Llc filed Critical Pfizer Vaccines Llc
Publication of IN2012DN00446A publication Critical patent/IN2012DN00446A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN446DEN2012 2009-07-30 2010-07-20 IN2012DN00446A (pm)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22986009P 2009-07-30 2009-07-30
PCT/IB2010/053313 WO2011013034A1 (en) 2009-07-30 2010-07-20 Antigenic tau peptides and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN00446A true IN2012DN00446A (pm) 2015-05-15

Family

ID=42941871

Family Applications (1)

Application Number Title Priority Date Filing Date
IN446DEN2012 IN2012DN00446A (pm) 2009-07-30 2010-07-20

Country Status (17)

Country Link
US (1) US20110177109A1 (pm)
EP (1) EP2459214A1 (pm)
JP (1) JP2013500326A (pm)
KR (2) KR20120049900A (pm)
CN (1) CN102596236B (pm)
AR (1) AR078085A1 (pm)
AU (1) AU2010277254B2 (pm)
CA (1) CA2768346A1 (pm)
CO (1) CO6612199A2 (pm)
IN (1) IN2012DN00446A (pm)
MX (1) MX2012001194A (pm)
NZ (2) NZ618391A (pm)
PE (1) PE20120817A1 (pm)
RU (2) RU2518291C2 (pm)
SG (1) SG177637A1 (pm)
TW (2) TWI461209B (pm)
WO (1) WO2011013034A1 (pm)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171829A1 (en) 2008-12-09 2011-07-28 Coley Pharm Group Inc Immunostimulatory oligonucleotides
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
CN102596221B (zh) 2009-06-10 2019-06-04 纽约大学 病理tau蛋白的免疫靶向
AU2013205313B2 (en) * 2010-10-07 2016-05-19 Ac Immune S.A. Phosphospecific antibodies recognising tau
TW201216985A (en) 2010-10-07 2012-05-01 Ac Immune Sa Pharmaceutical composition
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
MX339762B (es) 2011-09-28 2016-05-27 Univ Autonoma Del Estado De Morelos Metalopeptidos inmunomoduladores (immp) y composiciones que los contienen.
KR101981351B1 (ko) 2011-10-07 2019-09-02 에이씨 이뮨 에스.에이. 타우를 인식하는 포스포특이적 항체
CN104520322B (zh) 2012-04-05 2019-11-15 Ac免疫有限公司 人源化tau抗体
NZ703423A (en) * 2012-07-03 2018-02-23 Univ Washington Antibodies to tau
SG10201701181XA (en) 2012-08-16 2017-04-27 Ipierian Inc Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CA2902910A1 (en) 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
WO2015017280A1 (en) * 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
EP3104870A4 (en) 2014-02-14 2017-09-13 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
JP6913018B2 (ja) 2014-07-08 2021-08-04 ニューヨーク・ユニバーシティ タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
US20180050097A1 (en) * 2015-03-25 2018-02-22 Stc. Unm Immunotherapy compositions and methods for treatment of tauopathy and transgenic mouse
MA41669A1 (fr) 2015-07-06 2018-05-31 Ucb Biopharma Sprl Anticorps se liant a tau
JP6913078B2 (ja) 2015-08-13 2021-08-04 ニューヨーク・ユニバーシティ タウの短縮型Ａｓｐ４２１エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用
US11884707B2 (en) 2016-09-29 2024-01-30 Regeneron Pharmaceuticals, Inc. Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
US11958889B2 (en) * 2017-10-25 2024-04-16 Janssen Pharmaceuticals, Inc. Compositions of phosphorylated tau peptides and uses thereof
US11773148B2 (en) * 2017-10-27 2023-10-03 United Neuroscience Tau peptide immunogen constructs
CN109870581B (zh) * 2017-12-04 2021-05-04 厦门万泰凯瑞生物技术有限公司 一种定量检测HBsAg的试剂盒及方法
CN108314737B (zh) * 2018-01-25 2021-03-16 中国科学院过程工程研究所 一种重组蛋白及其制备方法和应用
CN110548135B (zh) * 2018-05-31 2023-06-06 长春百克生物科技股份公司 磷酸化多肽抗原疫苗及其制备方法和应用
GB201811382D0 (en) 2018-07-11 2018-08-29 Taylor John Hermon Vaccine
EP3861015A4 (en) 2018-10-07 2022-11-23 The University of British Columbia CONFORMATION SPECIFIC EPITOPES IN ALPHA-SYNUCLEIN, ANTIBODIES DIRECTED AGAINST AND METHODS THEREOF
WO2020163730A2 (en) 2019-02-08 2020-08-13 Ac Immune S.A. Method of safe administration of phosphorylated tau peptide vaccine
MX2021009440A (es) * 2019-02-08 2021-09-10 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
US20200291391A1 (en) * 2019-03-12 2020-09-17 Indi Molecular, Inc. Cross-linked epitopes and methods of use thereof
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
US12201679B2 (en) 2019-04-05 2025-01-21 Institute For Systems Biology Epitope-targeted peptide immunostimulants
JOP20210284A1 (ar) 2019-04-24 2023-01-30 Janssen Pharmaceuticals Inc الإعطاء غير المتجانس للقاحات تاو
WO2020236969A1 (en) 2019-05-20 2020-11-26 Indi Molecular, Inc. Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (ido1)
AU2020284288A1 (en) * 2019-05-27 2022-01-20 Promis Neurosciences Inc. Conformation-specific epitopes in tau, antibodies thereto and methods related thereof
GB2585252A (en) * 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
US12209142B2 (en) 2020-05-29 2025-01-28 Institute For Systems Biology SARS-CoV-2 epitope-targeted peptide immunostimulants
WO2022031342A1 (en) * 2020-08-07 2022-02-10 Othair Prothena Limited Tau vaccine for the treatment of alzheimer's disease
EP4212172A4 (en) * 2020-09-08 2024-10-16 Osaka University Immunogenic composition targeting phosphorylated tau protein
JP2024534976A (ja) * 2021-09-08 2024-09-26 ジョイント・ストック・カンパニー “バイオキャド” Ｍｈｃタンパク質に基づくヘテロ二量体を含む二重特異性抗体
CN118613496A (zh) * 2021-09-29 2024-09-06 杨森制药公司 安全施用Tau磷酸肽缀合物的方法
CN115894659B (zh) * 2022-10-19 2023-11-10 上海优宁维生物科技股份有限公司 微管相关蛋白Tau抗原及其制备方法和应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
JP2547714B2 (ja) 1981-10-23 1996-10-23 モルキユラ− バイオシステムズ インコ−ポレテツド オリゴヌクレオチド治療剤及びその製法
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
DE3525624A1 (de) 1985-07-18 1987-01-22 Celamerck Gmbh & Co Kg Insektizid wirksames mittel zur bekaempfung von textilschaedlingen
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
WO1992011291A1 (en) 1990-12-20 1992-07-09 Smithkline Beecham Biologicals (S.A.) Vaccines based on hepatitis b surface antigen
WO1993011231A1 (en) * 1991-12-06 1993-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Tools for the diagnosis and treatment of alzheimer's disease
EP0544942A1 (en) * 1991-12-06 1993-06-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel tools for the diagnosis and treatment of Alzheimer disease
US7408027B1 (en) * 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
WO1994000153A1 (en) 1992-06-25 1994-01-06 Smithkline Beecham Biologicals (S.A.) Vaccine composition containing adjuvants
ES2109685T5 (es) 1993-03-23 2005-09-01 Smithkline Beecham Biologicals S.A. Composiciones para vacunas que contienen monofosforil-lipido a 3-o-desacilado.
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5658738A (en) 1994-05-31 1997-08-19 Becton Dickinson And Company Bi-directional oligonucleotides that bind thrombin
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
WO1996030523A2 (en) 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
WO1997034145A1 (fr) * 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
EP1537877A3 (en) 1996-10-11 2005-08-03 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AU5508798A (en) * 1996-11-19 1998-06-10 Trustees Of The University Of Pennsylvania, The Diagnostic and therapeutic reagents for alzheimer's disease
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
DE69841122D1 (de) 1997-03-10 2009-10-15 Coley Pharm Gmbh Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
US6225292B1 (en) 1997-06-06 2001-05-01 The Regents Of The University Of California Inhibitors of DNA immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
NZ506245A (en) 1998-02-12 2003-08-29 Immune Complex Corp Strategically modified hepatitis b core proteins and their derivatives
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
CA2325939A1 (en) 1998-04-09 1999-10-21 Martin Friede Vaccine
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
ATE357252T1 (de) 1998-10-16 2007-04-15 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
ATE314095T1 (de) 1998-10-21 2006-01-15 Us Health Virusähnliche partikel zur induktion von autoantikörpern
DK1119630T3 (da) 1998-11-05 2006-05-15 Powderject Vaccines Inc Nukleinsyrekonstruktioner til genetisk immunisering
PL192016B1 (pl) 1998-11-30 2006-08-31 Cytos Biotechnology Ag Kompozycja, sposób wytwarzania sztucznego, uporządkowanego i powtarzalnego układu antygenu, zastosowanie kompozycji oraz kompozycja szczepionki
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
NZ513935A (en) 1999-02-17 2004-02-27 Csl Ltd Immunogenic complexes and methods relating thereto
PT1163000E (pt) 1999-03-19 2008-03-20 Glaxosmithkline Biolog Sa Vacina contra antigénios de bactérias
EP2322210A1 (en) 1999-04-19 2011-05-18 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
CZ20021045A3 (cs) 1999-09-24 2002-08-14 Smithkline Beecham Biologicals S. A. Pomocný prostředek
WO2001021207A2 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
EA200201077A1 (ru) 2000-04-07 2003-04-24 Юниверсити Оф Лидз Инновэйшнз Лимитед Коровые антигенные химерные белки гепатита в
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
WO2001098333A2 (en) 2000-06-22 2001-12-27 Celltech Pharmaceuticals Limited Modification of hepatitis b core antigen
EP1304947A1 (en) 2000-07-15 2003-05-02 Lighthouse Display International Limited Shelf edge display fittings
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
WO2003102165A2 (en) 2002-02-21 2003-12-11 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
CA2492823A1 (en) 2001-09-14 2003-03-27 Martin F. Bachmann In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
CA2492826C (en) 2001-09-14 2016-12-13 Cytos Biotechnology Ag Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
US20040176283A1 (en) 2002-04-01 2004-09-09 Robinson John A. Methods and compositions for the design of synthetic vaccines
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
WO2004007538A2 (en) 2002-07-17 2004-01-22 Cytos Biotechnology Ag Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
ATE506964T1 (de) * 2002-07-19 2011-05-15 Cytos Biotechnology Ag Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
KR100991679B1 (ko) 2002-12-10 2010-11-04 셀덱스 테라퓨틱스 리미티드 안정화 면역원성 ＨＢｃ 키메라 입자
NZ548352A (en) * 2003-12-17 2009-09-25 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
AU2005335104C1 (en) 2004-07-18 2010-10-28 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
CA2574090A1 (en) 2004-07-18 2006-12-21 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
EP1814917A2 (en) * 2004-10-13 2007-08-08 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
US8012936B2 (en) * 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
DE602006015421D1 (de) * 2006-04-13 2010-08-26 Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh HER-2/neu Multipeptidimpfstoff
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
CN102596221B (zh) * 2009-06-10 2019-06-04 纽约大学 病理tau蛋白的免疫靶向
FR3058624B1 (fr) 2016-11-15 2018-12-07 L'oreal Brosse pour l'application d'un produit sur les cils et/ou les sourcils

Also Published As

Publication number Publication date
NZ618391A (en) 2015-07-31
US20110177109A1 (en) 2011-07-21
KR20130127547A (ko) 2013-11-22
RU2014112002A (ru) 2015-10-10
MX2012001194A (es) 2012-03-07
AR078085A1 (es) 2011-10-12
TW201436804A (zh) 2014-10-01
CN102596236B (zh) 2015-06-24
NZ598356A (en) 2014-06-27
TW201106968A (en) 2011-03-01
AU2010277254A1 (en) 2012-02-09
TWI461209B (zh) 2014-11-21
KR20120049900A (ko) 2012-05-17
EP2459214A1 (en) 2012-06-06
CA2768346A1 (en) 2011-02-03
AU2010277254B2 (en) 2015-05-07
WO2011013034A1 (en) 2011-02-03
JP2013500326A (ja) 2013-01-07
SG177637A1 (en) 2012-03-29
WO2011013034A4 (en) 2011-04-28
RU2518291C2 (ru) 2014-06-10
CN102596236A (zh) 2012-07-18
RU2012102701A (ru) 2013-09-10
PE20120817A1 (es) 2012-07-07
CO6612199A2 (es) 2013-02-01

Similar Documents

Publication Publication Date Title
IN2012DN00446A (pm)
PH12016500040A1 (en) Pcsk9 vaccine
PH12013501636A1 (en) Treatment of osteoarthritis and pain
MX2011007930A (es) Conjugados de insulina cristalina.
IN2015DN02826A (pm)
TN2012000414A1 (en) Forms of rifaximin and uses thereof
EP2576578A4 (en) POLYMORPHES OF 2'-O-FUCOSYLLACTOSE AND MANUFACTURE THEREOF
IN2012DN02645A (pm)
IN2012DN02737A (pm)
MX2013004726A (es) Anticuerpos dkk1 y metodos de uso.
MX337723B (es) Vacuna de peptido ch3 de ige.
TN2011000374A1 (en) Antibody molecules having specificity for human ox40
IN2012DN02081A (pm)
AU2010329805B2 (en) New conjugates and compositions for immunotherapy and anti-tumoral treatment
MX2012007806A (es) Composiciones farmaceuticas para administracion oral de peptidos de insulina.
MX359854B (es) Anticuerpos anti-cxcr3.
MX2009009362A (es) Forma de dosificacion novedosa.
MX2013011421A (es) Derivados de pirazolo-pirimidina.
MY150931A (en) Substituted oxazolidinones and their use
MX2011012505A (es) Piperidinas sustituidas.
GB201118201D0 (en) Novel peptides
WO2014100857A8 (en) Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
UA107576C2 (ru) Замещенные пиперидины
MX2009009361A (es) Nueva forma de dosificacion.